AIM:TRX

Stock Analysis Report

Executive Summary

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally.

Snowflake

Fundamentals

Excellent balance sheet with limited growth.


Similar Companies

Share Price & News

How has Tissue Regenix Group's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-3.0%

TRX

0.1%

GB Biotechs

2.0%

GB Market


1 Year Return

-62.4%

TRX

26.3%

GB Biotechs

3.3%

GB Market

Return vs Industry: TRX underperformed the UK Biotechs industry which returned 26.3% over the past year.

Return vs Market: TRX underperformed the UK Market which returned 3.3% over the past year.


Share holder returns

TRXIndustryMarket
7 Day-3.0%0.1%2.0%
30 Day-7.2%2.8%-1.0%
90 Day-21.0%2.4%-1.7%
1 Year-62.4%-62.4%27.3%26.3%8.3%3.3%
3 Year-82.1%-82.1%12.0%10.0%19.0%4.5%
5 Year-86.8%-86.8%55.7%52.0%38.4%8.4%

Price Volatility Vs. Market

How volatile is Tissue Regenix Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Tissue Regenix Group undervalued based on future cash flows and its price relative to the stock market?

1.29x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Undervalued: Insufficient data to calculate TRX's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate TRX's fair value to establish if it is undervalued.


Price Based on Earnings

PE vs Industry: TRX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: TRX is unprofitable, so we can't compare its PE Ratio to the UK market.


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate TRX's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: TRX is good value based on its PB Ratio (1.3x) compared to the GB Biotechs industry average (2x).


Next Steps

Future Growth

How is Tissue Regenix Group expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

45.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: TRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TRX's revenue (30.6% per year) is forecast to grow faster than the UK market (4% per year).

High Growth Revenue: TRX's revenue (30.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: Insufficient data to determine if TRX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Tissue Regenix Group performed over the past 5 years?

-1.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: TRX is unprofitable, and losses have increased over the past 5 years at a rate of -1.8% per year.

Accelerating Growth: Unable to compare TRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Return on Equity

High ROE: TRX has a negative Return on Equity (-27.26%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: TRX is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: TRX is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Tissue Regenix Group's financial position?


Financial Position Analysis

Short Term Liabilities: TRX's short term assets (£16.8M) exceeds its short term liabilities (£4.1M)

Long Term Liabilities: TRX's short term assets (£16.8M) exceeds its long term liabilities (£6.5M)


Debt to Equity History and Analysis

Debt Level: TRX's debt to equity ratio (20.2%) is considered satisfactory

Reducing Debt: Insufficient data to determine if TRX's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: TRX has a low level of unsold assets or inventory.

Debt Coverage by Assets: TRX's debt is covered by short term assets (assets are 2.893780x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TRX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: TRX has sufficient cash runway for 1.145328 years if free cash flow continues to grow at historical rates of 21.6% each year.


Next Steps

Dividend

What is Tissue Regenix Group's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%5.4%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate TRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate TRX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if TRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TRX's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

What is the CEO of Tissue Regenix Group's salary, the management and board of directors tenure and is there insider trading?

0.2yrs

Average management tenure


CEO

Gareth Jones (50yo)

0.2yrs

Tenure

UK£179,134

Compensation

Mr. Gareth Hywel Jones has been an Interim Chief Executive Officer of Tissue Regenix Group plc since August 1, 2019 and serves as its Chief Operating Officer. He has been Company Secretary of Tissue Regeni ...


CEO Compensation Analysis

Compensation vs. Market: Gareth has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the UK market.

Compensation vs Earnings: Insufficient data to compare Gareth's compensation with company performance.


Management Age and Tenure

0.2yrs

Average Tenure

50yo

Average Age

Experienced Management: TRX's management team is not considered experienced ( 0.2 years average tenure), which suggests a new team.


Board Age and Tenure

3.3yrs

Average Tenure

50yo

Average Age

Experienced Board: TRX's board of directors are considered experienced (3.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • John Andrew Samuel (67yo)

    Executive Chairman

    • Tenure: 2yrs
    • Compensation: UK£111.00k
  • Daniel Lee

    President of US Operations

    • Tenure: 0.8yrs
  • Joel Pickering

    President of TRX BioSurgery

    • Tenure: 2.8yrs
  • Gareth Jones (50yo)

    Interim CEO

    • Tenure: 0.2yrs
    • Compensation: UK£179.13k
  • Caitlin Pearson

    Head of Communications

    • Tenure: 0yrs
  • Eileen Ingham

    Consultant

    • Tenure: 0yrs
  • Mike Barker (43yo)

    CFO & Executive Director

    • Tenure: 0.2yrs

Board Members

  • Jon Glenn (50yo)

    Non-Executive Director

    • Tenure: 3.8yrs
    • Compensation: UK£30.00k
  • John Andrew Samuel (67yo)

    Executive Chairman

    • Tenure: 2yrs
    • Compensation: UK£111.00k
  • Alan Jonathan Miller (54yo)

    Non-Executive Director

    • Tenure: 9.3yrs
    • Compensation: UK£35.00k
  • Shervanthi Homer-Vanniasinkam

    Non- Executive Director

    • Tenure: 3.3yrs
    • Compensation: UK£30.00k
  • Gareth Jones (50yo)

    Interim CEO

    • Tenure: 0.2yrs
    • Compensation: UK£179.13k
  • Randeep Grewal

    Non-Executive Director

    • Tenure: 6.3yrs
    • Compensation: UK£35.00k
  • Mike Barker (43yo)

    CFO & Executive Director

    • Tenure: 0.2yrs
  • Steven Arnoczky

    Member of Orthopedic Clinical Advisory Board for US

    • Tenure: 3.3yrs
  • David Caborn

    Member of Orthopedic Clinical Advisory Board for US

    • Tenure: 3.3yrs
  • Tom Carter

    Member of Orthopedic Clinical Advisory Board for US

    • Tenure: 3.3yrs

Company Information

Tissue Regenix Group plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Tissue Regenix Group plc
  • Ticker: TRX
  • Exchange: AIM
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£36.987m
  • Shares outstanding: 1.16b
  • Website: https://www.tissueregenix.com

Number of Employees


Location

  • Tissue Regenix Group plc
  • Unit 1 & 2
  • Astley Way
  • Leeds
  • West Yorkshire
  • LS26 8XT
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TRXAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPJun 2010
TSSN.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJun 2010

Biography

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and international ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/11 21:42
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)